Skip to main content

Advertisement

SpringerLink
Log in

Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes

  • Nephrology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Purpose

Teneligliptin is a novel DPP-4 inhibitor in development for treating type 2 diabetes mellitus that does not require dose adjustment for diabetic patients with end-stage renal disease; however, it had not been known whether or not teneligliptin is safe or potent in dialysis patients. We conducted a prospective study to assess the utility of teneligliptin for diabetic patients undergoing hemodialysis.

Methods

Blood glucose, glycated albumin, and HbA1c were measured every 4 weeks, at 4, 12, 20, and 28 weeks, and every 8 weeks, respectively, for patients treated with teneligliptin (n = 14; 7 patients newly started and 7 that switched from other medications) and patients of a control group who continued ongoing antidiabetic therapy (n = 29).

Results

Blood glucose level showed a 36.7 mg/dl decrease from 4 weeks in the teneligliptin group (p < 0.05). The differences in glycated albumin (at 28 w) and HbA1c (at 24 w) between the teneligliptin group and the control group were −3.1 % (p < 0.05) and −0.57 % (p = 0.057), respectively. These parameters also decreased in patients who switched from voglibose 0.2 mg t.i.d. or vildagliptin 50 mg qd after teneligliptin administration. No case with hypoglycemia was identified. One patient had the dose of a laxative administered for constipation increased; however, no patient ceased teneligliptin due to side effects.

Conclusion

Teneligliptin 20 mg is well tolerated, safe, and significantly improves glycemic control in diabetic patients with end-stage renal disease. Teneligliptin 20 mg once daily was considered to be more potent than voglibose 0.2 mg t.i.d. or vildagliptin 50 mg qd.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Bouchi R, Babazono T, Yoshida N et al (2010) Association of albuminuria and reduced estimated glomerular filtration rate with incident stroke and coronary artery disease in patients with type 2 diabetes. Hypertens Res 33:1298–1304

    Article  PubMed  Google Scholar 

  2. Freedman BI, Andries L, Shihabi ZK et al (2011) Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients. Clin J Am Soc Nephrol 6:1635–1643

    Article  CAS  PubMed  Google Scholar 

  3. Fukuoka K, Nakao K, Morimoto H et al (2008) Glycated albumin levels predict long-term survival in diabetic patients undergoing haemodialysis. Nephrology (Carlton) 13:278–283

    Article  CAS  Google Scholar 

  4. Inaba M, Maekawa K, Okuno S et al (2012) Impact of atherosclerosis on the relationship of glycemic control and mortality in diabetic patients on hemodialysis. Clin Nephrol 78:273–280

    Article  CAS  PubMed  Google Scholar 

  5. Williams ME, Lacson E Jr, Wang W, Lazarus JM, Hakim R (2010) Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and time-dependent Cox model analyses. Clin J Am Soc Nephrol 5:1595–1601

    Article  PubMed  Google Scholar 

  6. Feldt-Rasmussen B (2006) Is there a need to optimize glycemic control in hemodialyzed diabetic patients? Kidney Int 70:1392–1394

    Article  CAS  PubMed  Google Scholar 

  7. Inaba M, Okuno S, Kumeda Y et al (2007) Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 18:896–903

    Article  CAS  PubMed  Google Scholar 

  8. Kishimoto M (2013) Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetes Metab Syndr Obes 6:187–195

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Peacock TP, Shihabi ZK, Bleyer AJ et al (2008) Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int 73:1062–1068

    Article  CAS  PubMed  Google Scholar 

  10. Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W (2011) Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab 13:947–954

    Article  CAS  PubMed  Google Scholar 

  11. Eto T, Inoue S, Kadowaki T (2012) Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 14:1040–1046

    Article  CAS  PubMed  Google Scholar 

  12. Regeur L, Faber OK, Binder C (1978) Plasma C-peptide in uraemic patients. Scand J Clin Lab Invest 38:771–775

    Article  CAS  PubMed  Google Scholar 

  13. Robaudo C, Zavaroni I, Garibotto G, Deferrari G (1996) Renal metabolism of C-peptide in patients with early insulin-dependent diabetes mellitus. Nephron 72:395–401

    Article  CAS  PubMed  Google Scholar 

  14. Gallwitz B (2007) Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update). Drugs Today (Barc) 43:801–814

    Article  CAS  Google Scholar 

  15. Monami M, Iacomelli I, Marchionni N, Mannucci E (2010) Dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 20:224–235

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors report no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Urology and Nephrology, Nagakubo Hospital, 6907-1, Yaho, Kunitachi, Tokyo, 186-0011, Japan

    Hideo Otsuki, Takeo Kosaka, Kenzo Nakamura, Yoshitaka Kuwahara & Takuji Tsukamoto

  2. Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan

    Takeo Kosaka

  3. Sanwa Clinic, 3-1-8-501, Shibasakicho, Tachikawa, Tokyo, 190-0031, Japan

    Fumihiko Shimomura

Authors
  1. Hideo Otsuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takeo Kosaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kenzo Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fumihiko Shimomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshitaka Kuwahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takuji Tsukamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideo Otsuki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Otsuki, H., Kosaka, T., Nakamura, K. et al. Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes. Int Urol Nephrol 46, 427–432 (2014). https://doi.org/10.1007/s11255-013-0552-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-013-0552-6

Keywords

Search

Navigation